Can a pill outperform biologics for severe eczema?

NCT ID NCT07741838

Not yet recruiting Disease control Sponsor: AbbVie Source: ClinicalTrials.gov ↗

First seen Aug 03, 2026 · Last updated Aug 04, 2026 · Updated 1 time

Summary

This study looks at how well upadacitinib, a daily pill, works compared to biologic injections for people with moderate-to-severe atopic dermatitis (eczema). The goal is to see if more patients can reach a state of minimal disease activity, meaning nearly clear skin and little to no itching. Around 900 adults will be followed for 48 weeks in real-world settings, with their treatment chosen by their doctor as usual. The study will track skin severity and itch scores to compare the effectiveness of these treatments.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: upadacitinib and approved biologic treatments
What this could lead to: If upadacitinib proves more effective than biologics in real-world settings, it could become a preferred treatment option for moderate-to-severe atopic dermatitis, improving symptom control and quality of life.
What could go wrong: This is an observational study, so results may be influenced by patient differences and real-world variability. Upadacitinib carries risks like infections and blood clots, and effectiveness may vary among individuals.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atopic eczema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATOPIC DERMATITIS

More trials for these conditions

Other studies related to the condition(s) this trial covers.